Biosimilars trend report 2020

Home/Reports | Posted 20/11/2020 post-comment0 Post your comment

The seventh edition of the Biosimilars Trend Report 2020 has been published. This 2020 report was developed based on input from members of the healthcare community in the US [1].

23 AA011020

The report is split into sections to fully describe current biosimilar trends in the US. These are: the current state of the marketplace, trends of different therapeutics, key considerations for providers, payers, employers and patients, reimbursement, policy considerations and biosimilars in review.

The first biosimilar was launched in the US in 2015. The report notes that, as of early 2020, 28 biosimilars have been approved in the US, and 18 have launched. In the last year (since the 2019 report), there has been a 65% increase in the number of approved biosimilars and a 157% increase in those available. In addition, in the US, a number of mechanisms to support biosimilar uptake are now in place. These include the Centers for Medicare and Medicaid Services (CMS) which has established a Healthcare Common Procedure Coding System (HCPCS) and biosimilars payment rates which should support uptake and lead to healthcare savings. The report also highlights that US regulatory standards for biosimilar development, approval and establishment of interchangeability, are scientifically appropriate to protect patient safety and support confidence in them from providers and payers. These are key factors in a sustainable marketplace. Although financial savings are a key driver for biosimilar uptake, manufacturer reputation for high quality and reliability are also important. Manufacturers should also have an understanding of clinical, economic and operational needs of providers and payers, together with knowledge of what drives their decisions.

Overall, the report highlights that biosimilar adoption is not the only way to measure their success. When many biosimilars are available, the price of them, and reference products, can be driven down, which also demonstrates the success of biosimilars in terms of providing healthcare savings and creating more sustainable healthcare services.

Related articles
The US biosimilars market in 2020

FDA updates Purple Book database

US policy brief identifies barriers to biosimilars uptake

Amgen on both sides of the biosimilar arena

1. Amgen Biosimilars. 2020 Biosimilar Trends Report [homepage on the Internet]. [cited 2020 Nov 20]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010